Characterising patients and examining real-life outcomes for UK patients with COPD initiating on or changing to Fostair (REACH II)

Study identification

• EU PAS number:
  EUPAS9142
• Study ID:
  26266
• Official title and acronym:
  Characterising patients and examining real-life outcomes for UK patients with COPD initiating on or changing to Fostair (REACH II)
• DARWIN EU® study:
  No
• Study countries:
  United Kingdom
• Study description:
  Two-stage historical cohort study to evaluate, in a comparative effectiveness study, whether Fostair pMDI is non-inferior, in terms of COPD exacerbation prevention, to other fixed dose combination (FDC) inhaled corticosteroid (ICS) / long-acting beta agonist (LABA) COPD therapies.
• Study status:
  Finalised

Research institutions and networks

Institutions

Observational & Pragmatic Research Institute Pte (OPRI)

United Kingdom

Study timelines

Date when funding contract was signed

Planned:10/02/2015

Actual:10/02/2015

Study start date

Planned:07/04/2015

Actual:07/04/2015

Data analysis start date

Planned:20/04/2015

Actual:20/04/2015

Date of interim report, if expected

Planned:01/09/2017

Actual:01/09/2017

Date of final study report

Planned:11/09/2015

Actual:05/09/2017

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Chiesi Ltd

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable